Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J WirthEric ShermanBruce RobinsonBenjamin SolomonHyunseok KangJochen LorchFrancis WordenMarcia BroseJyoti PatelSophie LeboulleuxYann GodbertFabrice BarlesiJohn C MorrisTaofeek K OwonikokoDaniel S W TanOliver GautschiJared WeissChristelle de la FouchardièreMark E BurkardJanessa LaskinMatthew H TaylorMatthias KroissJacques MedioniJonathan W GoldmanTodd M BauerBenjamin LevyViola W ZhuNehal LakhaniVictor MorenoKevin EbataMichele NguyenDana HeirichEdward Y ZhuXin HuangLuxi YangJennifer KheraniS Michael RothenbergAlexander DrilonVivek SubbiahManisha H ShahMaria E CabanillasPublished in: The New England journal of medicine (2020)
In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).